A recent breakthrough study highlights how a simple at-home urine test could accurately detect prostate cancer. Researchers from Vanderbilt University and the University of Michigan suggest this ...
EDMONTON, AB, April 20, 2026 /PRNewswire/ - Nanostics Inc., a precision health company advancing diagnostic innovation through its ClarityDX (R) platform, today announced the publication of a ...
Prostate cancer is one of the most frequently diagnosed cancers in men yet is often highly treatable when detected early. It originates in the prostate gland, located between the bladder and the penis ...
Please provide your email address to receive an email when new articles are posted on . MyProstateScore 2.0 showed high sensitivity for detecting aggressive prostate cancer without the need for a ...
SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug ...
CAMBRIDGE, England--(BUSINESS WIRE)--Scientists in Cambridge have developed a new ‘super test’ for prostate cancer in an effort to revolutionise screening and diagnosis of the disease and accelerate ...
Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...
Researchers have found a simple at home urine test for prostate cancer screening is highly accurate. Researchers at Vanderbilt and the University of Michigan have shown that a simple at-home urine ...
Artera, a company that develops multimodal AI-based prognostic and predictive cancer tests, has been granted Breakthrough Device Designation by the FDA for its ArteraAI Prostate, an AI-enabled tool ...
A remarkable scientific advancement could transform how prostate cancer is detected in men around the world. Researchers have developed a groundbreaking urine test that offers significant advantages ...
Halfway through 5-year study, ExoDx Prostate Test offers more accurate stratification of high- and low-risk patients compared to standard of care MINNEAPOLIS, May 18, 2023 /PRNewswire/ -- Bio-Techne ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results